![Harald F. Stock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Harald F. Stock
Gründer bei Domus Diagnostics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Harpreet Singh-Jasuja | M | 50 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 24 Jahre |
Toni Weinschenk | M | 51 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 24 Jahre |
Paul W. D. Chapman | M | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.
Quantum Diamond Technologies, Inc.
![]() Quantum Diamond Technologies, Inc. Information Technology ServicesTechnology Services Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA.
Domus Diagnostics, Inc.
![]() Domus Diagnostics, Inc. Medical/Nursing ServicesHealth Services Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina. | 9 Jahre |
Steffen Walter | M | 47 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 19 Jahre |
Rainer Kramer | M | 60 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 12 Jahre |
John Fagan | M | - |
Consilient Health Ltd.
![]() Consilient Health Ltd. Pharmaceuticals: MajorHealth Technology Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005. | 4 Jahre |
Greg Espenhover | M | - |
Vitanova Biomedical, Inc.
![]() Vitanova Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016. | - |
Matt Gdovin | M | - |
Vitanova Biomedical, Inc.
![]() Vitanova Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016. | - |
Tom Roberts | M | - |
Vitanova Biomedical, Inc.
![]() Vitanova Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016. | 8 Jahre |
Seabron C. Adamson | M | - |
Quantum Diamond Technologies, Inc.
![]() Quantum Diamond Technologies, Inc. Information Technology ServicesTechnology Services Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA. | - |
Carsten Reinhardt | M | 57 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 15 Jahre |
Friedrich von Bohlen und Halbach | M | 61 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
Peter Chambré | M | 68 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | 12 Jahre |
John Reif | M | - |
Domus Diagnostics, Inc.
![]() Domus Diagnostics, Inc. Medical/Nursing ServicesHealth Services Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina. | - |
Arnd Christ | M | 57 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
John C. Pena | M | - |
Quantum Diamond Technologies, Inc.
![]() Quantum Diamond Technologies, Inc. Information Technology ServicesTechnology Services Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA. | - |
Erich Schlick | M | 72 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
Ronald Walsworth | M | - |
Quantum Diamond Technologies, Inc.
![]() Quantum Diamond Technologies, Inc. Information Technology ServicesTechnology Services Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA. | 12 Jahre |
Xin Song | M | - |
Domus Diagnostics, Inc.
![]() Domus Diagnostics, Inc. Medical/Nursing ServicesHealth Services Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina. | - |
Roger Wu | M | - |
Consilient Health Ltd.
![]() Consilient Health Ltd. Pharmaceuticals: MajorHealth Technology Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005. | 4 Jahre |
John Dixon | M | - |
Consilient Health Ltd.
![]() Consilient Health Ltd. Pharmaceuticals: MajorHealth Technology Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005. | - |
Luke Crosbie | M | - |
Consilient Health Ltd.
![]() Consilient Health Ltd. Pharmaceuticals: MajorHealth Technology Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005. | 19 Jahre |
Craig Slingluff | M | - |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | - |
Karin Louise Dorrepaal | M | 63 | 12 Jahre | |
Heather Mason | F | 63 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Christof Hettich | M | 64 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Cedrik M. Britten | M | 49 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 4 Jahre |
Joseph Gentile | M | - |
Domus Diagnostics, Inc.
![]() Domus Diagnostics, Inc. Medical/Nursing ServicesHealth Services Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina. | - |
Mikhail D. Lukin | M | - |
Quantum Diamond Technologies, Inc.
![]() Quantum Diamond Technologies, Inc. Information Technology ServicesTechnology Services Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA. | - |
Matthias Kromayer | M | 58 |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | - |
Shane Reihill | M | 58 |
Consilient Health Ltd.
![]() Consilient Health Ltd. Pharmaceuticals: MajorHealth Technology Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christopher A. Bleck | M | 66 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Christopher M. Lindblom | M | 52 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | - |
Jonathan L. Tilly | M | 61 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Christoph Westphal | M | 56 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Arthur Tzianabos | M | 60 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Stephen Kraus | M | 47 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Heinz-Gerd Suelmann | M | 58 |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | 10 Jahre |
Marc Kozin | M | 62 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 4 Jahre |
John Sexton | M | 81 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | - |
Theresa McNeely | F | 60 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Ralf Eisenhauer | M | 55 |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
Jonathan Gillis | M | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 5 Jahre |
John P. Howe | M | 81 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Mary Fisher | F | 62 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 5 Jahre |
Sun Altbach | F | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 2 Jahre |
Markus Ziener | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Thomas Senderovitz | M | 57 |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | 3 Jahre |
Jochen Hummel | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Karsten Bahlmann | M | - |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
Angela Geerling | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Oscar Ferenczi | M | 60 |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | 5 Jahre |
Katina Dorton | F | 66 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 2 Jahre |
Matthias H. Werner | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Mona Welschof | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Helmut Hufnagel | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Rebecca J. Peterson | F | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 1 Jahre |
Thomas Ulmer | M | 45 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 2 Jahre |
James D. Luterman | M | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | - |
Daniela Mattheus | F | 51 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Simon Read | M | 53 |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | 5 Jahre |
Christophe Couturier | M | 58 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 1 Jahre |
Filmon Zerai | M | - |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Juan Carlos Jaramillo | M | 53 |
Grünenthal GmbH
![]() Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | 2 Jahre |
Mumin Demiral | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Andreas Maderna | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Sandra Albert | F | 47 |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
William Steinkrauss | M | 39 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 1 Jahre |
David Gaiero | M | 45 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 2 Jahre |
Melanie Rolli | M | 51 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
David Floyd | M | 63 |
DePuy Orthopaedics, Inc.
![]() DePuy Orthopaedics, Inc. Medical SpecialtiesHealth Technology DePuy Orthopaedics, Inc. engages in the design, manufacture, and distribution of orthopedic devices and supplies. Its products are used primarily by orthopedic medical specialists and spinal neurosurgeons in both surgical and non-surgical therapy. The company was founded on December 13, 2016 and is headquartered in Warsaw, IN. | 4 Jahre |
Yi Zhun Zhu | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Silvia Fazio | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Alison Lawton | F | 62 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 1 Jahre |
Stacy Powell McMahan | F | 60 |
DePuy Orthopaedics, Inc.
![]() DePuy Orthopaedics, Inc. Medical SpecialtiesHealth Technology DePuy Orthopaedics, Inc. engages in the design, manufacture, and distribution of orthopedic devices and supplies. Its products are used primarily by orthopedic medical specialists and spinal neurosurgeons in both surgical and non-surgical therapy. The company was founded on December 13, 2016 and is headquartered in Warsaw, IN. | 2 Jahre |
David Harding | M | 58 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 1 Jahre |
Walter Wenninger | M | 86 | - | |
Klaus Breiner | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Sven Weber | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Thomas F. Widmann | M | 77 |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 8 Jahre |
Youming Zhang | M | 60 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Jeffrey E. Young | M | 51 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 2 Jahre |
Oliver Wintermantel | M | - |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
Ilke Hildegard Panzer | F | 58 |
DePuy Orthopaedics, Inc.
![]() DePuy Orthopaedics, Inc. Medical SpecialtiesHealth Technology DePuy Orthopaedics, Inc. engages in the design, manufacture, and distribution of orthopedic devices and supplies. Its products are used primarily by orthopedic medical specialists and spinal neurosurgeons in both surgical and non-surgical therapy. The company was founded on December 13, 2016 and is headquartered in Warsaw, IN. | 2 Jahre |
Ravi Mehrotra | M | - |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | - |
Martin Bürmann | M | 55 |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Ina Schlie | F | 57 |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Ilinca Rosetti | M | 50 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Marcus Furch | M | 56 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Louis Villalba | M | 55 |
OvaScience, Inc.
![]() OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | 3 Jahre |
Paul Grant Higham | M | - |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | 7 Jahre |
Annelies Goos | F | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Rolf Wiswesser | M | - |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Bernhard Hofer | M | - | 8 Jahre | |
Axel Hoos | M | 54 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
Thomas Sullivan | M | 60 |
DePuy Orthopaedics, Inc.
![]() DePuy Orthopaedics, Inc. Medical SpecialtiesHealth Technology DePuy Orthopaedics, Inc. engages in the design, manufacture, and distribution of orthopedic devices and supplies. Its products are used primarily by orthopedic medical specialists and spinal neurosurgeons in both surgical and non-surgical therapy. The company was founded on December 13, 2016 and is headquartered in Warsaw, IN. | 2 Jahre |
Marc Hambach | M | - |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
Michael Albrecht | M | 74 |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
Jochen Müller | M | 58 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
Lena Thiede | F | - |
Ruprecht-Karls-Universität Heidelberg
| 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 54 | 54,00% |
Vereinigte Staaten | 49 | 49,00% |
Irland | 5 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Harald F. Stock
- Persönliches Netzwerk